# US 8,278,417 B2 · Kits for treating wounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,417 B2
- Document ID: US8278417B2
- Status: Granted
- Kind: B2
- Application number: 13/442,943
- Filed: 2012-04-10
- Published: 2012-09-06
- Granted: 2012-10-02
- Earliest claimed: 2010-02-03
- Assignees: Stemnion, Inc.
- Inventors: Vivienne S. Marshall; Charlotte A. Smith; Catherine J. Trumpower; George L. Sing; Linda O. Palladino
- Web page: https://patentgrep.com/patent/US8278417B2

## CPC

- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.

## Claims

### Claim 1

A kit for use in a method for healing a wound comprising packaging material, an extraembryonic cell-derived cellular cytokine solution composition comprising physiologic concentrations of VEGF, TGFβ2, Angiogenin, PDGF, TIMP-1 and TIMP-2, wherein the physiologic concentration is ˜5.0-16 ng/mL for VEGF, ˜3.5-4.5 ng/mL for Angiogenin, ˜100-165 pg/mL for PDGF, ˜2.5-2.7 ng/mL for TGFβ2, ˜0.68 μg mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, and instructions for the use of the composition to heal a wound, wherein the wound is selected from the group consisting of a surgical incision of the skin or fascia, an ulcer on the skin or a mucous membrane, and a burn.

### Claim 2

A kit for use in a method for healing a wound comprising packaging material, an amnion-derived cellular cytokine solution composition comprising physiologic concentrations of VEGF, TGFβ2, Angiogenin, PDGF, TIMP-1 and TIMP-2, wherein the physiologic concentration is ˜5.0-16 ng/mL for VEGF, ˜3.5-4.5 ng/mL for Angiogenin, ˜100-165 pg/mL for PDGF, ˜2.5-2.7 ng/mL for TGFβ2, ˜0.68 μg mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, and instructions for the use of the composition to heal a wound, wherein the wound is selected from the group consisting of a surgical incision of the skin or fascia, an ulcer on the skin or a mucous membrane, and a burn.

### Claim 3

A kit for use in a method for healing a wound comprising packaging material, a physiologic cytokine solution composition comprising a therapeutic component consisting of physiologic concentrations of:
a) VEGF, TGFβ2, Angiogenin, PDGF, TIMP-1 and TIMP-2; and
b) a carrier, wherein the physiologic concentration is ˜5.0-16 ng/mL for VEGF, ˜3.5-4.5 ng/mL for Angiogenin, ˜100-165 pg/mL for PDGF, ˜2.5-2.7 ng/mL for TGFβ2, ˜0.68 μg mL for TIMP-1 and ˜1.04 μg/mL for TIMP-2, wherein the carrier is normal saline, PBS, lactated Ringer's solution or cell culture medium, and instructions for the use of the composition to heal a wound, wherein the wound is selected from the group consisting of a surgical incision of the skin or fascia, an ulcer on the skin or a mucous membrane, and a burn.

### Claim 4 (depends on 1, 2)

The kit of claim 1, 2, or 3 wherein the composition is formulated for sustained-release.
